ESMO 2021 | DS-7300 for the treatment of advanced solid tumors

Elena Garralda, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, talks on the potential of DS-7300 for the treatment of solid tumors. DS-7300 is an antibody-drug conjugate (ADC) targeting B7-H3, an immune regulatory protein that is overexpressed in several tumor types. The high payload of this ADC makes it an attractive new treatment option. A recent Phase I/II study the investigating DS-7300 in 70 patients showed promising efficacy results and an acceptable safety profile. Nevertheless, there was one patient who died due to interstitial lung disease, which is an adverse effect that has been previously observed with other ADCs with exatecan derivative payloads. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.